Apontis Pharma AG

XETRA APPH.DE

Apontis Pharma AG Return on Capital Employed (ROCE) for the year ending December 31, 2023: -31.99%

Apontis Pharma AG Return on Capital Employed (ROCE) is -31.99% for the year ending December 31, 2023, a -544.75% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Apontis Pharma AG Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 7.19%, a 1,379.06% change year over year.
  • Apontis Pharma AG Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 0.49%, a 109.07% change year over year.
  • Apontis Pharma AG Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -5.36%, a 67.13% change year over year.
  • Apontis Pharma AG Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -16.31%.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
SV Wall Street
XETRA: APPH.DE

Apontis Pharma AG

CEO Mr. Bruno Wohlschlegel
IPO Date May 11, 2021
Location Germany
Headquarters Alfred-Nobel-Str. 10
Employees 177
Sector Healthcare
Industries
Pharmaceuticals Drugstores & Retail Pharmacies
Description

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

StockViz Staff

February 6, 2025

Any question? Send us an email